Concentrations	6 Months Ended	12 Months Ended
Jun. 30, 2022	Dec. 31, 2021
Risks and Uncertainties [Abstract]
CONCENTRATIONS	NOTE 7 – CONCENTRATIONS Customer Concentration For the six months ended June 30, 2022 and 2021, no customer accounted for over 10% of total revenues from apparel sales included in discontinued operations. For the six months ended June 30, 2022 and 2021, one licensee accounted for 100% total revenues from customer license fee. Vendor Concentrations For the six months ended June 30, 2022 and 2021, one licensor accounted for 100% of the Company’s vendor license agreements (see below) related to the Company’s biopharmaceutical operation.	NOTE 9 – CONCENTRATIONS Customer Concentration For the years ended December 30, 2021 and 2020, no customer accounted for over 10% of total revenues from apparel sales included in discontinued operations. Vendor Concentrations For the year ended December 31, 2021, one licensor accounted for 100% of the Company’s vendor license agreements (see Note 10) related to the Company’s biopharmaceutical operation. For the year ended December 31, 2020, the Company did not have any licensor.

Concentrations

6 Months Ended

12 Months Ended

Jun. 30, 2022

Dec. 31, 2021

NOTE 7 – CONCENTRATIONS

Customer Concentration

For the six months ended June 30, 2022 and 2021, no customer accounted for over 10% of total revenues from apparel sales included in discontinued operations.

For the six months ended June 30, 2022 and 2021, one licensee accounted for 100% total revenues from customer license fee.

Vendor Concentrations

For the six months ended June 30, 2022 and 2021, one licensor accounted for 100% of the Company’s vendor license agreements (see below) related to the Company’s biopharmaceutical operation.

NOTE 9 – CONCENTRATIONS

Customer Concentration

For the years ended December 30, 2021 and 2020, no customer accounted for over 10% of total revenues from apparel sales included in discontinued operations.

Vendor Concentrations

For the year ended December 31, 2021, one licensor accounted for 100% of the Company’s vendor license agreements (see Note 10) related to the Company’s biopharmaceutical operation.

For the year ended December 31, 2020, the Company did not have any licensor.